/IMVT
IMVT Stock - Immunovant, Inc.
Healthcare|BiotechnologyNASDAQ
$26.68+1.91%
+$0.50 (+1.91%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).64
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+6.8%upside
Target: $28.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMVT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$26.41 – $26.95
TARGET (TP)$28.50
STOP LOSS$24.55
RISK/REWARD1:0.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.56
52W High$27.69
52W Low$12.72
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-438,152,000 | $-270,209,000 | $-208,276,000 | $-156,033,000 | $-108,117,000 |
| Net Income | $-413,840,000 | $-259,336,000 | $-210,960,000 | $-156,730,000 | $-107,431,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 |
Company Overview
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
12
75%
Hold / Neutral
4
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
12 Bullish4 Neutral/Bearish
Price Targets
$35
Average Target
↑ 30.4% Upside
Now
$5
Low
$35
Average
$55
High
Based on 20 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 14th 2025 | Truist | Initiation | Hold | $16 |
| July 10th 2025 | Goldman | Resumed | Neutral | $18 |
| March 3rd 2025 | Jefferies | Initiation | Hold | $20 |
| January 3rd 2025 | Wolfe Research | Downgrade | Peer Perform | - |
| October 10th 2024 | Raymond James | Resumed | Outperform | $36 |
| October 9th 2024 | Oppenheimer | Reiterated | Outperform | $53← $47 |
| March 28th 2024 | Oppenheimer | Initiation | Outperform | $50 |
| March 13th 2024 | Goldman | Initiation | Buy | $50 |
| February 20th 2024 | JP Morgan | Initiation | Overweight | $51 |
| February 15th 2024 | Wolfe Research | Initiation | Outperform | $55 |
| December 12th 2023 | Deutsche Bank | Initiation | Buy | $50 |
| October 13th 2023 | UBS | Upgrade | Buy | $55← $18 |
| September 26th 2023 | Raymond James | Upgrade | Outperform | $40 |
| May 1st 2023 | BofA Securities | Initiation | Buy | $26 |
| April 25th 2023 | Citigroup | Initiation | Buy | $28 |
Earnings History & Surprises
IMVTBeat Rate
28%
Last 18 quarters
Avg Surprise
-6.3%
EPS vs Estimate
Beats / Misses
5/12
1 met exactly
Latest EPS
$-0.73
Q4 2025
EPS Surprise History
Q1 24
+16.3%
$-0.36vs$-0.43
Q2 24
-20.9%
$-0.52vs$-0.43
Q3 24
-13.2%
$-0.60vs$-0.53
Q4 24
-23.3%
$-0.74vs$-0.60
Q1 25
-4.1%
$-0.76vs$-0.73
Q2 25
+10.3%
$-0.64vs$-0.71
Q3 25
+13.0%
$-0.60vs$-0.69
Q4 25
-1.4%
$-0.73vs$-0.72
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 27, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $-0.72 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.72 | $-0.73 | -1.4% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.69 | $-0.60 | +13.0% | ✓ BEAT |
Q2 2025 | May 29, 2025 | $-0.71 | $-0.64 | +10.3% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $-0.73 | $-0.76 | -4.1% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.60 | $-0.74 | -23.3% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.53 | $-0.60 | -13.2% | ✗ MISS |
Q2 2024 | May 29, 2024 | $-0.43 | $-0.52 | -20.9% | ✗ MISS |
Q1 2024 | Feb 12, 2024 | $-0.43 | $-0.36 | +16.3% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.47 | $-0.45 | +4.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.45 | $-0.57 | -26.7% | ✗ MISS |
Q2 2023 | May 22, 2023 | $-0.43 | $-0.46 | -7.0% | ✗ MISS |
Q1 2023 | Feb 3, 2023 | $-0.39 | $-0.49 | -25.6% | ✗ MISS |
Q4 2022 | Nov 4, 2022 | $-0.39 | $-0.41 | -5.1% | ✗ MISS |
Q3 2022 | Aug 5, 2022 | $-0.40 | $-0.35 | +12.5% | ✓ BEAT |
Q2 2022 | Jun 8, 2022 | $-0.38 | $-0.41 | -7.9% | ✗ MISS |
Q1 2022 | Feb 4, 2022 | $-0.33 | $-0.36 | -9.1% | ✗ MISS |
Q4 2021 | Nov 5, 2021 | $-0.28 | $-0.35 | -25.0% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.31 | $-0.31 | 0.0% | = MET |
Latest News
Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $28
➖ NeutralBenzinga•Dec 15, 2025, 05:48 PM
Immunovant Files For Offering Of 26.2M Shares Of Common Stock
📉 NegativeBenzinga•Dec 12, 2025, 11:14 AM
IMVT stock has given up its prior loss. Immunovant shares were trading lower after the company priced a $550 million common stock offering.
➖ NeutralBenzinga•Dec 11, 2025, 02:42 PM
Immunovant shares are trading lower after the company priced a $550 million common stock offering.
📉 NegativeBenzinga•Dec 11, 2025, 12:42 PM
Immunovant Announced $550M Underwritten Common Stock Offering To Provide Runway Through Potential Graves' Disease Commercial Launch Of IMVT-1402
➖ NeutralBenzinga•Dec 11, 2025, 07:34 AM
IMVT stock has given up its prior gain. Immunovant shares were trading higher.
📉 NegativeBenzinga•Nov 10, 2025, 02:40 PM
Immunovant shares are trading higher. The company reported Q2 EPS results.
📈 PositiveBenzinga•Nov 10, 2025, 02:09 PM
Immunovant Q2 EPS $(0.73) Misses $(0.72) Estimate
📉 NegativeBenzinga•Nov 10, 2025, 12:03 PM
Watching Immunovant; Shares Moving Higher, Traders Circulate Unconfirmed Rumor Co Mentioned By M&A Blog
📈 PositiveBenzinga•Oct 30, 2025, 02:06 PM
Immunovant gains amid takeover speculation
📈 PositiveSeeking Alpha•Oct 30, 2025, 02:04 PM
Truist Securities Initiates Coverage On Immunovant with Hold Rating, Announces Price Target of $16
➖ NeutralBenzinga•Oct 14, 2025, 01:11 PM
JP Morgan Maintains Overweight on Immunovant, Lowers Price Target to $33
➖ NeutralBenzinga•Sep 30, 2025, 12:29 PM•Also:
HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $35 Price Target
📈 PositiveBenzinga•Sep 4, 2025, 10:39 AM
Immunovant Reports Durability And Treatment-Free 6-Month Remission Data; Unveils ~80% Response Rate In Off-Treatment Graves' Disease Study
📈 PositiveBenzinga•Sep 3, 2025, 05:00 PM
Immunovant Posts 34% R&D Jump in Q1
➖ NeutralThe Motley Fool•Aug 11, 2025, 11:27 AM
Frequently Asked Questions about IMVT
What is IMVT's current stock price?
Immunovant, Inc. (IMVT) is currently trading at $26.68 per share. The stock has moved +1.91% today.
What is the analyst price target for IMVT?
The average analyst price target for IMVT is $28.50, based on 1 analyst.
What sector is Immunovant, Inc. in?
Immunovant, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMVT's market cap?
Immunovant, Inc. has a market capitalization of $4.68 billion, making it a mid-cap company.
Does IMVT pay dividends?
No, Immunovant, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to IMVT for comparison